Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Plans for FY2018 Fee Schedule Revision Now Up for Public Comments
January 15, 2018
- Novo’s Semaglutide Up for MHLW Panel Review Jan. 26 after Approval Hold
January 15, 2018
- MHLW Orders Label Revisions for Abilify, 4 Other APIs
January 12, 2018
- Streamlining Regulations of Pharmaceutical Affairs to Be “a Top Priority” in 2018: MHLW Pharma Bureau Chief
January 12, 2018
- MHLW Proposes Add’l Conditions for Penalty Medical Fee Cuts: Chuikyo
January 11, 2018
- Balancing Innovation and Universal Coverage Was Key in Drug Pricing Reform: Health Minister
January 10, 2018
- PMDA Chief Says Next Challenge Is to Boost Review Quality, Global Expansion Drive
January 9, 2018
- MHLW Unofficially Notified Companies of Products Eligible for New PMP: Sources
January 9, 2018
- MHLW Study Group Approves Framework for Comprehensive Guidelines on Pharmacotherapy in the Elderly
January 9, 2018
- Counterfeit Drug Panel OKs Final Report, MHLW to Issue GDP Guidelines in FY2018
December 27, 2017
- Council OKs Public Knowledge-Based Application for Diagnogreen, Valixa
December 26, 2017
- MHLW OKs Add’l Indications for Keytruda, Soliris and More
December 26, 2017
- Japan Cabinet OKs FY2018 Budget, 52.9 Billion Yen Earmarked for Urgent Drug Discovery Package
December 25, 2017
- “Comprehensive Strategy” Updated after 2 Years, MHLW to Mull Procedures for Info Handover for Brand-Name Meds Bowing Out of Market
December 25, 2017
- Single Price Band Rule for Generics to Get Underway in April 2020: MHLW
December 22, 2017
- Mogamulizumab Gets Orphan Status for HTLV-1-Associated Myelopathy
December 22, 2017
- Chuikyo Wraps Up CEA Debate for This Year, Sorts Out Issues towards Full Rollout
December 22, 2017
- 4th or Later Players Could Also Qualify for PMP If Post-Launch “True Clinical Utility” Premium Granted: MHLW
December 21, 2017
- Outline of Drug Pricing Reform Package
December 21, 2017
- Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…